靶点- |
作用机制- |
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1996-10-01 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1996-09-26 |
Phase III study combined with post-marketing clinical study of RM1319 in patients with inborn errors of bile acid metabolism, including children - Phase III study combined with post-marketing clinical study of RM1319 in patients with inborn errors of bile acid metabolism, including children
Safety study of NaPPS in pediatric patients with mucopolysaccharidosis type VI
Safety study of NaPPS in pediatric patients with mucopolysaccharidosis type VI
100 项与 ReqMed Co., Ltd. 相关的临床结果
0 项与 ReqMed Co., Ltd. 相关的专利(医药)
Carrer path. Novartis/biocamp: dream, challenge and presure
Come over Inter-college, Bioseries
New encounter especially when things were bad
100 项与 ReqMed Co., Ltd. 相关的药物交易
100 项与 ReqMed Co., Ltd. 相关的转化医学